Previous 10 | Next 10 |
ImmunoGen (NASDAQ: IMGN ): Q1 GAAP EPS of -$0.30 beats by $0.03 . More news on: ImmunoGen, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Encouraging Efficacy Signal Observed in Pre-Specified Subset of Patients in Phase 3 FORWARD I Study; Company to Meet with Regulators this Quarter to Discuss Potential Path Forward for Mirvetuximab Soravtansine Monotherapy FORWARD II Trial with Mirvetuximab Combinations Continues to Enr...
Editor's Note: The summary bullets for this article were chosen by Seeking Alpha Read more ...
ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, May 3, 2019 to discuss its first quarter operating results. Management wi...
Noteworthy events during the week of March 24 - 30 for healthcare investors. More news on: Cidara Therapeutics, Inc., Recro Pharma, Inc., Autolus Therapeutics plc, Healthcare stocks news, , Read more ...
Roche ( RHHBY ) announced that it had received European approval for MabThera to treat patients with pemphigus vulgaris ((PV)). This approval is a good one, because it will help expand the market opportunity for MabThera. Especially, since the company had already received approval for th...
Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. Evoke Pharma Tumbles After Preliminary NDA Review News: Recently, Evoke Pharma ( EVOK ) tumbled by 51% on the announcement that the FDA was not sat...
CORAL GABLES, FL / ACCESSWIRE / March 6, 2019 / The ascendancy of the biotech stock market to where it is today has only been made possible by the fact that biotech companies continue to formulate and manufacture top-of-the-line technologies for the purpose of the betterment of the human e...
Invitae (NYSE: NVTA ) initiated with Buy rating and $29 (43% upside) price target at Chardan Capital Markets. Shares up 2% premarket. More news on: Invitae, ImmunoGen, Inc., Zoetis, Stocks on the move, Healthcare stocks news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Klepierre (KLPEF) is expected to report for Q4 2023 comScore Inc. (SCOR) is expected to report $0.8 for Q4 2023 Universal Stainless & Alloy Products Inc. (USAP) is expected to report for Q4 2023 FAT Brands Inc. (FAT) is expected to report $-1.55 for Q4 2023 Jet.AI Inc. (JTAI) ...
AbbVie Completes Acquisition of ImmunoGen PR Newswire Adds flagship antibody-drug conjugate (ADC) ELAHERE ® (mirvetuximab soravtansine-gynx) for folate receptor-alpha (FRα) positive platinum-resistant ovarian cancer (PROC) to AbbVie's portfolio ...
2024-02-10 09:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...